Elixinol will continue to be produced for the UK under a licensing agreement with British Cannabis despite the company pulling out of the UK and European markets after missing the boat on novel food applications.
The company was keen on pushing full spectrum CBD products in every country and made significant investments in Europe to support that but then realised the UK would be a better strategic move. Unfortunately by that point it had missed the chance to submit a novel food application, CBD-Intel was told.
Sign up to access our business and regulatory briefings and get the most updated news, insights and our expert analysis to keep you on top of worldwide industry trends.
By signing up you agree to our Terms and Conditions Please note trial access may take up to 24 hours to be granted as access must be qualified by a member of the CBD-Intel team.
